Abstract:This review covers five key areas: (1) What has happened in the last 10 years? (2) From symptomatic to disease‐modifying therapy: Symptomatic therapy: neurotransmitter‐based strategies and Disease‐modifying therapy: chromosomal inactivation versus gene dosage correction; (3) Multimodal therapy: accounting for the syndromic nature of trisomy 21; (4) Neurotherapy; and (5) Lost in translation: why do therapies fail in clinical trials in Down syndrome? In the last decade, an important effort was made in the field of Down syndrome to find new interventions that improve cognition. These therapies have added to the traditional symptomatic treatments and to the drugs for treating Alzheimer disease in the general population repurposed for Down syndrome. Defining next‐generation therapeutics will involve biomarker‐based therapeutic decision‐making, and preventive and multimodal interventions. However, translation of specific findings into effective therapeutic strategies has been disappointingly slow and has failed in many cases at the clinical level, leading to reduced credibility of mouse studies. This is aggravated by a tendency to favour large‐magnitude effects and highly significant findings, leading to high expectations but also to a biased view of the complex pathophysiology of Down syndrome. Here, we review some of the most recent and promising strategies for ameliorating the cognitive state of individuals with Down syndrome. We studied the landscape of preclinical and clinical studies and conducted a thorough literature search on PubMed and ClinicalTrials.gov for articles published between June 2012 and August 2022 on therapies for ameliorating cognitive function in individuals with Down syndrome. We critically assess current therapeutic approaches, why therapies fail in clinical trials in Down syndrome, and what could be the path forward. We discuss some intrinsic difficulties for translational research, and the need for a framework that improves the detection of drug efficacy to avoid discarding compounds too early from the companies' pipelines.

Chromosomal and cellular therapeutic approaches for Down syndrome: A research update

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.

Human Chromosome 21 Orthologous Region on Mouse Chromosome 17 is a Major Determinant of Down Syndrome-Related Developmental Cognitive Deficits.

Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome

Single‐cell landscape analysis reveals systematic senescence in mammalian Down syndrome

Realizing the Potential of Exploiting Human IPSCs and Their Derivatives in Research of Down Syndrome

A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

A new mouse model for Down syndrome

State‐of‐the‐art therapy for Down syndrome

Trisomy silencing by XIST: translational prospects and challenges

The burden of trisomy 21 disrupts the proteostasis network in Down syndrome

Genome-wide expression analysis in Down syndrome: insight into immunodeficiency

Competing Endogenous RNAs Crosstalk in Hippocampus: A Potential Mechanism for Neuronal Developing Defects in Down Syndrome

Single cell atlas of trisomy 21 cerebral cortex

overdosage induces mid-face shortening through downregulation in Down syndrome models

Consequences of trisomy 21 for brain development in Down syndrome

What people with Down Syndrome can teach us about cardiopulmonary disease

Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome

Down syndrome and the complexity of genome dosage imbalance

Single-nucleus RNA sequencing reveals cell type-specific transcriptome alterations of Down syndrome hippocampus using the Dp16 mouse model

Survey of Human Chromosome 21 Gene Expression Effects on Early Development in Danio rerio